Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96GK7
UPID:
FAH2A_HUMAN
Alternative names:
-
Alternative UPACC:
Q96GK7; Q9Y3B0
Background:
Fumarylacetoacetate hydrolase domain-containing protein 2A, encoded by the gene symbol Q96GK7, is postulated to exhibit hydrolase activity. This protein is part of a broader family of enzymes that play crucial roles in various biochemical pathways, including the breakdown of complex molecules.
Therapeutic significance:
Understanding the role of Fumarylacetoacetate hydrolase domain-containing protein 2A could open doors to potential therapeutic strategies. Its hypothesized hydrolase activity suggests it may be involved in key metabolic processes, making it a target of interest for drug discovery efforts aimed at treating metabolic disorders.